Vinorelbine - Latest Advances

A network model for patient-derived drug response in breast cancer integrating multi-omics datasets.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

Journal: OncoTargets and therapy

Published: June 11, 2025

Identification of Molecular Subtypes and a Novel Prognostic Model for Lung Squamous Cell Carcinoma Based on Adenylate Uridylate (AU)-Rich Element Genes.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: June 11, 2025

Stress granules promote quiescence by enhancing p21 levels and reducing phospho-Rb.

Journal: RNA (New York, N.Y.)

Published: June 07, 2025

Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 131 centres.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 21, 2025

Phage-coated vinorelbine-loaded hexagonal boron nitride for targeted lung cancer therapy via chemo-photothermal treatment.

Journal: Bioorganic chemistry

Published: May 13, 2025

Identification of YAP regulators through high-throughput screening and NanoBiT-based validation-drug repositioning for cancer therapy.

Journal: Animal cells and systems

Published: May 12, 2025

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.

Journal: Anti-cancer drugs

Published: May 06, 2025

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.

Journal: Translational lung cancer research

Published: May 06, 2025

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Journal: Breast (Edinburgh, Scotland)

Published: April 29, 2025

A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.

Journal: Genes & genomics

Published: April 24, 2025

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 18, 2025

Filters

A network model for patient-derived drug response in breast cancer integrating multi-omics datasets.

A network model for patient-derived drug response in breast cancer integrating multi-omics datasets.

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

Identification of Molecular Subtypes and a Novel Prognostic Model for Lung Squamous Cell Carcinoma Based on Adenylate Uridylate (AU)-Rich Element Genes.

Identification of Molecular Subtypes and a Novel Prognostic Model for Lung Squamous Cell Carcinoma Based on Adenylate Uridylate (AU)-Rich Element Genes.

Stress granules promote quiescence by enhancing p21 levels and reducing phospho-Rb.

Stress granules promote quiescence by enhancing p21 levels and reducing phospho-Rb.

Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 131 centres.

Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 131 centres.

Phage-coated vinorelbine-loaded hexagonal boron nitride for targeted lung cancer therapy via chemo-photothermal treatment.

Phage-coated vinorelbine-loaded hexagonal boron nitride for targeted lung cancer therapy via chemo-photothermal treatment.

Identification of YAP regulators through high-throughput screening and NanoBiT-based validation-drug repositioning for cancer therapy.

Identification of YAP regulators through high-throughput screening and NanoBiT-based validation-drug repositioning for cancer therapy.

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.

A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.